WHO ICTRP trial
MERMAID-1
JPRN-jRCT2080225282 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080225282 |
|---|---|
| Public title | MERMAID-1 |
| Scientific title | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1) |
| Primary sponsor | AstraZeneca KK |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | United States;Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;India;Israel;Italy;Korea;Mexico;Netherlands;Peru;Poland;Romania;Russian… |
| Conditions | This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III… |
| Interventions | investigational material(s) Generic name etc : Durvalumab/Placebo INN of investigational material : - Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : "Durvalumab 1500 mg or… |
| Registration date | Jul 19, 2020 |
| Target size | 31 |
| Secondary IDs | NCT04385368;JapicCTI-205378 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: